Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation
Vijay G. Sankaran, … , David F. Bishop, David P. Steensma
Vijay G. Sankaran, … , David F. Bishop, David P. Steensma
Published February 23, 2015
Citation Information: J Clin Invest. 2015;125(4):1665-1669. https://doi.org/10.1172/JCI78619.
View: Text | PDF | Corrigendum
Brief Report Hematology

X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation

  • Text
  • PDF
Abstract

Macrocytic anemia with abnormal erythropoiesis is a common feature of megaloblastic anemias, congenital dyserythropoietic anemias, and myelodysplastic syndromes. Here, we characterized a family with multiple female individuals who have macrocytic anemia. The proband was noted to have dyserythropoiesis and iron overload. After an extensive diagnostic evaluation that did not provide insight into the cause of the disease, whole-exome sequencing of multiple family members revealed the presence of a mutation in the X chromosomal gene ALAS2, which encodes 5′-aminolevulinate synthase 2, in the affected females. We determined that this mutation (Y365C) impairs binding of the essential cofactor pyridoxal 5′-phosphate to ALAS2, resulting in destabilization of the enzyme and consequent loss of function. X inactivation was not highly skewed in wbc from the affected individuals. In contrast, and consistent with the severity of the ALAS2 mutation, there was a complete skewing toward expression of the WT allele in mRNA from reticulocytes that could be recapitulated in primary erythroid cultures. Together, the results of the X inactivation and mRNA studies illustrate how this X-linked dominant mutation in ALAS2 can perturb normal erythropoiesis through cell-nonautonomous effects. Moreover, our findings highlight the value of whole-exome sequencing in diagnostically challenging cases for the identification of disease etiology and extension of the known phenotypic spectrum of disease.

Authors

Vijay G. Sankaran, Jacob C. Ulirsch, Vassili Tchaikovskii, Leif S. Ludwig, Aoi Wakabayashi, Senkottuvelan Kadirvel, R. Coleman Lindsley, Rafael Bejar, Jiahai Shi, Scott B. Lovitch, David F. Bishop, David P. Steensma

×

Figure 2

Severe LOF with the ALAS2 Y365C mutation and lack of highly skewed X inactivation in female mutation carriers.

Options: View larger image (or click on image) Download as PowerPoint
Severe LOF with the ALAS2 Y365C mutation and lack of highly skewed X ina...
(A) Model of ALAS2 shows PLP highlighted in blue and the Y or C amino acid at position 365 highlighted in red. (B) SDS-PAGE gel of WT and mutant ALAS2. Lanes 1 and 8 contain the protein standards, while lanes 2–4 and 5–7 contain WT and mutant ALAS2 protein samples, respectively. Lanes 2 and 5 show partially purified samples after amylose affinity chromatography, lanes 3 and 6 show results after factor Xa digestion, and lanes 4 and 7 show results after gel filtration chromatography. Thin vertical lines in this composite figure separate noncontiguous lanes in the 2 original gels. (C) Chromatographic profiles for purification of WT and mutant ALAS2 by size exclusion (absorbance at 280 nm is shown in milliabsorbance units [mAU]). (D) Quantification of HUMARA results in all affected individuals showing WT and mutant X chromosomes. (E) Sanger sequencing traces of genomic DNA (gDNA) and cDNA derived from reticulocyte mRNA from the proband (II-2) for ALAS2, with an arrow highlighting the mutation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts